Search results
Pfizer Inc. (NYSE:PFE) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 1 day agoPfizer Inc. (NYSE:PFE) Q1 2024 Earnings Call Transcript May 1, 2024 Pfizer Inc. beats earnings...
Cardiff Oncology Inc (CRDF) (Q1 2024) Earnings Call Transcript Highlights: Strategic Insights ...
GuruFocus.com via Yahoo Finance· 10 hours agoThe FDA will evaluate the efficacy and safety differences between the doses used in the CRDF-004 trial to approve the dose for the pivotal trial. For the ...
US opens COVID vaccine to little kids, shots begin next week
AOL· 4 days agoThe U.S. on Saturday opened COVID-19 vaccines to infants, toddlers and preschoolers. The shots will...
Biotech’s bind over China bill
Politico· 2 hours agoCEO Stéphane Bancel touted the vaccine candidate’s safety and efficacy data as “stronger...the shot’s presentation — a pre-filled syringe — could be a game-changing differentiator for busy health ...
Earnings call: Cardiff Oncology reports on CRDF-004 trial progress By Investing.com
Investing.com· 4 hours agoCardiff Oncology, a biopharmaceutical company focused on developing new treatments for cancer, has...
Biodexa gains license for polyposis asset as stock more than doubles
Pharmaceutical Technology via Yahoo Finance· 4 days agoThe primary endpoints of the study are safety and tolerability...precancerous and can lead to...
Most RA Patients Meet EMA's JAK Inhibitor Warning Criteria
Medscape· 13 hours agoRecent regulatory warnings could mean that four in five patients with RA may not be prescribed JAK...
Unable to work since COVID vaccination, Gatineau man pins hopes on compensation
CBC via Yahoo News· 4 days agoA Gatineau, Que., man who developed a debilitating skin ailment after receiving a COVID-19 vaccine...
Chasing Novo and Lilly: The obesity drugs that could challenge Wegovy and Zepbound
BioPharma Dive via Yahoo Finance· 4 days agoLarge and small drugmakers are vying for a piece of what analysts view as one of the biggest market...
Eli Lilly assures investors it can overcome the high-quality problem of too much demand
CNBC· 3 days agoEli Lilly 's raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. The numbers leave little doubt that the long-term Eli Lilly ...
